Alogliptin Benzoate
The benzoate salt form of alogliptin, a DPP-4 inhibitor used to improve blood sugar control in type 2 diabetes by prolonging the action of incretin hormones that stimulate insulin release after meals. This formulation provides predictable oral absorption and once-daily dosing convenience.
Molecular Weight
461.5000 g/mol
TPSA
131.00 Ų
Therapeutic Areas
Mechanism of Action
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
2D Structure
Cite this structure
Embed this structure
SMILES
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O.O=C(O)c1ccccc1
InChI
InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1
Molecular Formula
C25H27N5O4
HBD / HBA
2 / 7
Rotatable Bonds
4
Heavy Atoms
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
The benzoate salt form of alogliptin, a DPP-4 inhibitor used to improve blood sugar control in type 2 diabetes by prolonging the action of incretin hormones that stimulate insulin release after meals. This formulation provides predictable oral absorption and once-daily dosing convenience.
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Yes, Alogliptin Benzoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL227529. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 16088021. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alogliptin-benzoate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alogliptin-benzoate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alogliptin-benzoate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alogliptin-benzoate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alogliptin-benzoate"></drugfyi-drug>